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Abstract
Background: Long QT syndrome (LQTS) is an inherited arrhythmic disorder characterized by prolongation of the
QT interval, a risk of syncope, and sudden death. There are already a number of causal genes in LQTS, but not all
LQTS patients have an identified mutation, which suggests LQTS unknown genes.
Methods: A cohort of 178 LQTS patients, with no mutations in the 3 major LQTS genes (KCNQ1, KCNH2, and SCN5A),
was screened for mutations in the transient potential melastatin 4 gene (TRPM4).
Results: Four TRPM4 variants (2.2% of the cohort) were found to change highly conserved amino-acids and were either
very rare or absent from control populations. Therefore, these four TRPM4 variants were predicted to be disease causing.
Furthermore, no mutations were found in the DNA of these TRPM4 variant carriers in any of the 13 major long QT
syndrome genes. Two of these variants were further studied by electrophysiology (p.Val441Met and p.Arg499Pro). Both
variants showed a classical TRPM4 outward rectifying current, but the current was reduced by 61 and 90% respectively,
compared to wild type TRPM4 current.
Conclusions: This study supports the view that TRPM4 could account for a small percentage of LQTS patients. TRPM4
contribution to the QT interval might be multifactorial by modulating whole cell current but also, as shown in Trpm4−/−
mice, by modulating cardiomyocyte proliferation. TRPM4 enlarges the subgroup of LQT genes (KCNJ2 in Andersen
syndrome and CACNA1C in Timothy syndrome) known to increase the QT interval through a more complex pleiotropic
effect than merely action potential alteration.
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Background
Congenital long QT syndrome (LQTS) is characterized
by a prolonged QT interval on the electrocardiogram
(ECG), and can lead to cardiac events such as syncope
or sudden cardiac death due to torsade de pointes or
ventricular fibrillation. Prevalence in the population is
about 1 over 2000 to 3000 [1, 2].
Similarly to other cardiomyopathies, a number of
genes were described to be responsible for LQTS. To
date, 15 genes have already been identified with more
than 700 mutations in LQTS patients [3, 4]. Six of these
genes encode for pore-forming ion channel subunits,
while others encode for regulatory subunits or proteins.
Among ion channel genes, mutations in KCNQ1 and
KCNH2, which encode voltage-gated K+ channels in-
volved in cardiac action potential (AP) repolarization,
are responsible for about 70% of LQTS [3]. Mutations of
the voltage-gated Na+ channel encoded by the SCN5A
gene are responsible for 1.7 to 8% of LQTS while muta-
tions in other genes are rare (below 1% of LQTS).
Altogether, the quest to find mutations remains elusive in
about 25% of LQTS patients [5], which leaves place for
the discovery of additional causal genes for this syndrome.
At the mechanistic level, LQT is mainly explained by a
delayed ventricular repolarization due to a prolongation
of AP in ventricular cardiomyocytes. It explains why loss
of function mutations in voltage-gated K+ channel
encoding genes, such as KCNQ1 and KCNH2, which
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participate in cardiomyocyte repolarization (AP phases
2–3), result in LQTS. Similarly, any ion channel known
to participate in the shape of AP may be involved in
LQTS. Several clues pointed to the transient potential
melastatin 4 gene (TRPM4) as a pertinent contender for
LQTS: 1- TRPM4 encodes a non-selective cation chan-
nel and the mRNA is present in the heart [6]. 2- TRPM4
currents were recorded in cardiomyocytes of several
mammals including humans [7]. 3- Trpm4−/− mice have
an increased QT interval [8]. 4- TRPM4 mutations were
reported in patients with other cardiac electrical distur-
bances such as, cardiac conduction block [9, 10] and
Brugada syndrome [11]. The involvement of TRPM4
in several pathologies is reminiscent to the voltage-
gated Na+ channel encoded by SCN5A, which was
associated with LQTS, Brugada syndrome, and con-
duction blocks [12].
According to this, we hypothesized that TRPM4 vari-
ants might be linked to LQTS. To address this hypoth-
esis, we screened a cohort of 178 patients with LQTS
and had no identified mutations in the major LQTS
genes (KCNQ1, KCNH2 and SCN5A). TRPM4 variants
were found in 4 patients (2.2% of the cohort). The elec-
trophysiological properties of 2 of these mutants were
further studied. Both mutations resulted in a decrease of
function of the TRPM4 channel.
Methods
Study population
In this study, 178 patients from the University Hospitals
of Nantes and Lyon were tested. This study was ap-
proved by the local ethics committees (comité de protec-
tion des personnes Ouest IV and Sud-Est II) and is in
accordance with the last version of the Declaration of
Helsinki [13]. In all probands, the clinical diagnosis of
LQTS was made using the Schwartz criteria [14, 15].
The QT interval was corrected by the formula of Bazett
(QTc). Each patient underwent full medical examination
to rule out syndromic forms of LQT. Blood samples
were collected after written informed consent. All study
participants provided written informed consent to par-
ticipate to this study. All these probands were negative
after mutation screening by dHPLC or direct sequencing
in the KCNQ1, KCNH2, and SCN5A genes. The LQTS
cohort of the University Hospital of Nantes (90 patients)
had also been tested negative for copy number variations
with a Multiple Ligation-dependent Probe Amplification
test of MRC Holland (SALSA P114 MLPA, MRC-
Holland, Amsterdam, the Netherlands). This test con-
tains 20 probes interrogating the KCNQ1 gene, 9 for the
KCNH2 gene, and 3 for the SCN5A gene [15]. The
LQTS cohort of the University Hospital of Lyon (88
patients) was also negative for mutation in the KCNE1
and KCNE2 genes.
Genetic analysis
DNA was extracted from blood samples according to
standard protocols. DNA concentration and quality were
assessed using NanoDrop (Thermo Fisher Scientific, Vil-
lebon sur Yvette, France) and Qubit (Life technologies,
Villebon sur Yvette, France) fluorometers. A260/A280
ratios of 1.8 to 2.0 and A260/A230 ratios >1.5 were ac-
cepted. Mutation screening of TRPM4 (ENST00000252826,
NM_017636.3, human genome version GRCh37/hg19) was
carried out by High Resolution Melting (HRM) analysis
(Rotor-Gene Q, Qiagen, Courtaboeuf, France), followed by
bi-directional sequencing of abnormal profiles or by direct
sequencing. The primers were already published [10]. Vari-
ants were confirmed on a second sample and PCR product.
For miniexome sequencing, enrichment of DNA samples
was performed with the Nextera Rapid Capture Exome
v1.0 kit (Illumina, San Diego, CA, USA). Sequencing was
carried out on a NextSeq500 instrument (Illumina, San
Diego, CA, USA) with a high-output flow cell. TruSight
One targets 4813 clinically relevant genes and covers
12 Mb of genomic content. In particular, the following long
QT genes are included: ANK2, CACNA1C, CALM1, CAV3,
KCNE1, KCNE2, KCNJ2, KCNJ5, KCNQ1, SCN4B, SCN5A
and SNTA1. A minimal coverage of 10x was obtained on
98.2% of target sequences. Bam files were loaded on
Alamut Visual 2.7.1 (Interactive Biosoftware, Rouen,
France) and the 13 long QT genes were sequentially
visualized along with the sequence reads of each pa-
tient. A threshold of 30% was selected to highlight se-
quence variants. The coverage of all coding exons of
LQ long genes was at least 10x.
Preparation of TRPM4 mutants
The complete human wild-type TRPM4 cDNA was cloned
in a pcDNA4/TO vector (Invitrogen, Cergy Pontoise,
France) [10]. Mutants were obtained by in vitro mutagen-
esis using QuickChange II site-directed mutagenesis kit
(Agilent Technologies, Massy, France). Mutant cDNA
clones were then systematically resequenced before using
them in further experiments.
Stable TRPM4 mutant expression
PcDNA4/TO plasmid containing the 2 selected TRPM4
mutants, were used to transfect T-REx™ 293 cell lines
with Lipofectamine 2000 (Invitrogen, Cergy Pontoise,
France) according to manufacturer specifications. The
T-REx™ 293 cell line stably expresses the tetracycline re-
pressor protein, enabling the silencing of the gene of
interest unless tetracycline is added to the culture
medium. T-REx™ 293 was obtained by stably transform-
ing HEK 293 cells with a plasmid containing the Tet re-
pressor cDNA under the control of the human CMV
promoter. Several stable clones (3–4) of each TRPM4
mutants were obtained according to Invitrogen protocol,
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by selecting with blasticidin (Tet repressor) and zeocin
(TRPM4). These stable clones were used for the electro-
physiological study.
Electrophysiological recordings
Patch-clamp experiments on T-REx™ 293 transfected
cells were performed at room temperature. An Axopatch
200B (Axon Instruments, Sunnyvale, CA, USA) amplifier
was used and controlled by a Pentium PC connected by
a Digidata 1322A A/D converter (Axon Instruments). It
was also used for data acquisition and analysis using
Pclamp software (Axon Instruments). Signals were
filtered at 1 kHz using an 8-pole Bessel low pass filter
before digitization at 10 kHz and storage. Patch pipettes
resistance was typically 2 MΩ when filled with intracel-
lular solution (below).
TRPM4 currents were recorded in the whole-cell con-
figuration using a ramp protocol. The holding potential
was −60 mV. The 400 ms increasing ramp from −100 to
+100 mV ends with a 20 ms step at +100 mV to unmask
a typical TRPM4 current [16]. The measured current
was then reported to cell size estimated by capacitance
measurement. A new ramp was performed every 5 s.
TRPM4 current develops with time after the membrane
break to stabilize within 10–20 min as previously shown
[16]. Biophysical properties were estimated after current
stabilization. Pipette solutions contained (in mM) 156
CsCl, 1 MgCl2 and 10 HEPES (pH adjusted to 7.2 with
CsOH and [Ca2+] 10−4 M). Bath and perfused solutions
contained (in mM) 156 NaCl, 5 CaCl2, 10 glucose and
10 HEPES (pH adjusted to 7.4 with NaOH).
Data analysis
Mutant electrophysiological parameters were compared
to wild type using an unpaired Student t test, with a
probability value below 0.05 considered as significant. A
Fisher exact test was performed to compare the preva-
lence of TRPM4 variants in the ethnically matched
control population, and in the LQTS cohort both of
European origin.
Results
Study subjects and TRPM4 screening
The screening of TRPM4 in the cohort of 178 Long QT
cases with no mutations in the 3 major LQT genes
(KCNH2, KCNQ1, and SCN5A) evidenced 4 variants of
interest (Table 1): p.V441M, p.R499W, p.R499P, and
p.G844D. The putative pathogenicity of these variants
was estimated on their prevalence in ethnically matched
control populations, the interspecies conservation of ref-
erence amino acid, the physico-chemical gap between
referenced and new residues, and prediction software
(snp&go [17], PhD_SNP [18], SNAP [19] and Pre-
dictSNP1.0 [20]). The data is summarized in Table 1. All
variants were new [9–11, 21] except p.G844D, which
was already found in cases of conduction blocks [10, 21]
and of Brugada syndrome [11]. All variants were hetero-
zygous. To exclude that any of these 4 Patients had a
variant in an already known long QT genes, the sequen-
cing of a panel of 4813 clinically relevant genes was ob-
tained from each patient. A careful reading with Alamut
Visual 2.7.1 of sequence reads of each TRPM4 variant
carriers did not detect any suspicious variant in coding
exons of any of the 13 long QT genes (ANK2, CAC-
NA1C, CALM1, CAV3, KCNE1, KCNE2, KCNH2,
KCNJ2, KCNJ5, KCNQ1, SCN4B, SCN5A and SNTA1)
tested with TruSight One gene panel. Interestingly, this
gene panel includes the TRPM4 gene. It was thus pos-
sible to confirm the reported TRPM4 variant of each of
the 4 Patients.th=tlb=
The clinical details of the 4 variant carriers are pre-
sented in Table 2. The range of age of discovery was
wide from 3 months to 69 years of age. Circumstances
of discovery were essentially related to disturbance in
consciousness.th=tlb=
Patient 1 had hypertension, type II diabetes and was
over-weighted. He was first seen at the cardiology clinics
because he was complaining about a shortness of breath
during exercise. He had a normal echocardiography and
normal coronarography but a prolonged QTc interval
was discovered. He was given 20 mg daily of Netaxolol.
Four years later, he was 68 years old. He lost conscious-
ness for several minutes while at rest. His wife noticed
that he had neither seizures nor urine loss. He recovered
consciousness spontaneously. Upon arrival of the
emergency unit, his heart rate was low (30/min) with
numerous premature ventricular beats occurring at
the down-sloping part of the T wave and a QTc at
500 ms. However, no torsade-de-pointes were re-
corded during his monitoring. He had hypokaliemia
(2.8 mEq/L) although he did not take any diuretic.
He received potassium and the dosage of betablocker
was lowered. Two years later, he started developing a
mild cardiac failure and his ECG showed, in addition
to the long QT, a left anterior hemiblock (Fig. 1). His
echocardiogram showed a mild concentric hyper-
trophy (10 mm), a normal ejection fraction and a dia-
stolic dysfunction. We consider a Schwartz score of 4
for this patient (QTc ≥ 480 ms and syncope at rest).
Patient 2 was a three-year-old baby when he had his
first loss of consciousness. As he was sleeping, he had a
cry. The parents who rushed to his bed noticed that he
was unreactive and atonic for several minutes. Then, he
recovered progressively. He was pale with circumoral
cyanosis and he vomited. At hospital, he had an echocar-
diography which disclosed a patent foramen ovale, a
prolonged QTc interval. A pH-metry showed no evi-
dence for a gastro-oesophageal reflux. Blood analysis
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was in normal range. He had an ambulatory ECG which
showed no arrhythmia. Subsequently, he had 3 losses of
consciousness in the following year with no detection of
any other anomalies except mild hypothermia (35.6 °C).
Figure 2 presents one representative ECG. We gave a
Schwartz score of 3.5 to this patient (QTc between 460
and 479 ms, syncope at rest and a slow heart rate for his
age). His asymptomatic older sister and parents had a
normal QTc interval.
Patient 3 is a 69-year-old female who lost conscious-
ness while gardening. She recovered consciousness
after an unknown lap of time and felt several epi-
sodes of dizziness during the following hours. Her
ECG showed a prolonged QT interval (Fig. 3) and
Holter recording discovered short stretches of ven-
tricular beats (Fig. 4). Her echocardiogram was nor-
mal and her blood tests were normal. She was given
a regular regimen of betablocker and did not
experience any other episodes of loss of conscious-
ness. In our opinion, her Schwartz score is 3.5 (QTc
in the range of 460–479 ms or torsade-like arrhythmia
and effort-associated syncope).
Patient 4, a fifteen-year-old boy, had a syncope while
he was at rest. The next day at the hospital, his ECG
showed a prolonged QTc interval but no arrhythmia
(Fig. 5). He had a rSr’ QRS complex in V2 but the QRS
duration was normal (90 ms). His echocardiography was
normal. His Schwartz score is 4.5 (QTc ≥ 480 ms, syn-
cope and a familial case of unexplained sudden death).
It was not possible to obtain blood samples from rela-
tives of these patients.
TRPM4 currents in the whole-cell configuration
HEK-293 TRPM4 transfected cells were searched for
ion currents using patch-clamp recordings in the
whole-cell configuration. Wild type (WT) TRPM4
Table 2 Patients characteristics
















Other cardiac LQT score




2 p.R499W M 3 m 4 Fainting
episodes
No 86 120 None 394 471 - 3.5
3 p.R499P F 69 y Fainting No 68 140 None 440 469 Ventricular
arrhythmia
3.5
4 p.G844D M 15 y Resuscitated
SCD
Yes 58 134 None 498 490 - 4.5
Abbreviations: ECG electrocardiogram, LAHB Left Anterior HemiBlock, mo month, QTc corrected QT interval (Bazett formula), SCD resuscitated Sudden Cardiac
Death, y year
Fig. 1 ECG of Patient 1: This patient was 70 years old at the time of ECG. He had a left anterior hemiblock and a QTc interval at 539 ms (QT 560 ms
and heart rate 56/min)
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transfected cells exhibited a characteristic outward
rectifying current with a density measured at
+100 mV of 191 ± 25 pA/pF (n = 18), significantly
higher than non-transfected HEK-293 cells (3 ± 1 pA/
pF; n = 11, p < 0.001), which is in accordance with
previous reports [11, 16].
Both, Val441Met and Arg499Trp, produced an out-
ward rectifying current of 74.6 ± 33 pA/pF (n = 7)
and 20 ± 7 pA/pF (n = 9) respectively, which is
significantly higher than the untransfected cells (p =
0.014 and p = 0.020, respectively) but smaller than
WT transfected cells (p = 0.016 and p < 0.001, re-
spectively) (Fig. 6a and b). To characterize the
current rectification, the current at +100 mV was
expressed as a ratio to the current at −60 mV
(Fig. 6c). No significant variation was induced by
mutations when compared to WT, indicating that
this parameter was not affected.
Fig. 2 ECG of Patient 2: The boy was 9 years old at the time recording of this ECG. He had a heart rate at 86/min, QT 394 ms and QTc 471 ms as
measured automatically
Fig. 3 ECG of Patient 3: This 69-year-old female patient had a heart rhythm at 68/min, QT 440 ms and QTc 469 ms
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Discussion
Four coding variants, which occurred in less than 0.3%
of more than 18,000 control chromosomes (and less
than 0.02% of more than 78,000 control chromosomes,
if G844D is excepted), were identified in 178 LQT cases
with no mutations in the 13 major LQTS genes. Among
the genes associated with long QT syndrome, only
AKAP9 and CALM2 are not included in the clinical ex-
ome of Illumina. AKAP9 was associated with a single
case of long QT syndrome [22] and might rather be a
QT interval modifier than a long QT causal gene [23].
CALM2 mutations may result in neonatal bradycardia,
cardiac arrest at a young age, a markedly prolonged QTc
interval and eventually mild neurodevelopmental delay
[24, 25]. Only two patients of this TRPM4 study were
within the age range of CALM2 mutations (Patients 2
and 4) but their QTc interval was never markedly pro-
longed as in CALM2 mutations.
The TRPM4 variants of this study are all heterozygous
missense variants. Interestingly, one patients had in
addition to LQTS, a conduction block (patient 1 had a
Left Anterior Hemiblock) but he was 70 years old when
the heart block appeared. This is consistent with Trpm4
−/− mice, which also present multilevel conduction
blocks [8] in addition to increased QT interval. The
variant of patient 4 (p.G844D) was found in other
cases with conduction blocks [10, 21] or Brugada syn-
drome [11]. Among these latter cases, one also had a
prolonged QTc interval of 458 ms (patient 13 of ref-
erence 11).
In this study, comparing whole-cell currents recorded
from WT and Val441Met and Arg499Trp TRPM4 trans-
fected HEK293 cells, showed densities significantly lower
in both variants. The present study does not discrimin-
ate between a decrease in current density due to a modi-
fication of biophysical/regulatory properties of the ion
channel, or a decreased protein expression as previously
reported for other TRPM4 mutants [11]. However, there
is a clear channel loss of function at the level of the
membrane.
Until now, TRPM4 impact on cardiac activity was in-
vestigated only with regards to its contribution to the ac-
tion potential (AP). According to its non-selective cation
permeability (Na+ and K+), its opening is suspected to
induce an outward repolarizing current in positive volt-
ages but an inward depolarizing current in negative volt-
ages. Since channel activity increases with membrane
depolarization, it is suspected to be largely open at the
upstroke and during the plateau of the AP. This is po-
tentiated by the fact that TRPM4 is activated by internal
Ca2+, which increases during the AP. Altogether, one
can predict that TRPM4 activation reduces phase 2
duration of AP and prolongs phase 3 counteracting re-
polarization. It seems that the effect on phase 2 is pre-
dominant, at least in mouse atria, since TRPM4
pharmacological inhibition by 9-phenanthrol reduces AP
Fig. 4 Holter ECG of Patient 3: This recording showed a short bout of ventricular arrhythmia occurring the afternoon of her morning syncope
Fig. 5 ECG of Patient 4: This boy had a heart rate at 58/min, QT 498 ms and QTc 490 ms
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duration [26]. Consistent with this result, Trpm4−/− mice
exhibit a shortened AP in atria, but also in ventricle
[26, 27]. Surprisingly, ECGs from Trpm4−/− mice
showed a prolonged QT interval, despite the reduc-
tion of ventricular AP duration [8, 27]. The rationale
for this counter-intuitive change might be that Trpm4
−/− mice also show an increased heart/body weight ra-
tio, which is not due to cardiomyocyte hypertrophy
but rather neonatal hyperplasia [8]. QT duration de-
pends on both ventricular AP duration and AP propa-
gation within the ventricle. Thus, hyperplasia could
increase the time for the excitation to reach the en-
tire ventricles, and thus prolong the QT interval.
Even if AP parameters are different between mice and
human, the model of Trpm4−/− mice might be repre-
sentative of heart disease related to TRPM4 mutations
in human. Indeed, mutations which induce loss of
function may impact cardiac development as does
Trpm4 disruption in mice. TRPM4 is not the first
gene encoding a channel whose mutations result in
LQT and developmental anomalies as it was already
found in Andersen [28] and Timothy [29] syndromes.
Unfortunately, contribution of the TRPM4 current to
these phases of the AP was not evaluated yet in hu-
man. It was also not possible to estimate a putative
cardiomyocyte hyperplasia in patients of this study.
At least, it can be stated that none of the five TRPM4
variant carriers fulfilled the echographic criteria for
hypertrophic cardiomyopathy.
Conclusion
This study supports the view that TRPM4 variants could
be responsible for about 2% of LQT syndrome cases.
The impact of these variants might result not only in
electrophysical disturbances, but putatively also in other
anomalies including cell proliferation.
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